Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Isbel García Figueredo

Institute of Oncology and Radiobiology
Cuba

Title: Role of testosterone and estrogen in prostate cancer risk

Biography

Biography: Isbel García Figueredo

Abstract

Aim: To identify if testosterone, estradiol and PSAT are related to the risk of developing prostate cancer.
Material and Methods: A case-control study was performed in 115 patients with benign prostatic hyperplasia (BPH), prostate cancer and controls, which underwent prostate surgery. The total PSA (TPSA), total testosterone (T) and estradiol (E) were quantified by IRMA kits, with biopsy as reference test. Multivariate logistic regression analysis was performed to evaluate the association with the presence of cancer.
Results: Although statistical differences between cancer patients and patients with BPH and those relative to the control (P <0.001), concerning the three markers, they did not show a high specificity. The T to TPSA ratio and E to TPSA ratio could discern between the three groups of patients with high sensitivity (100% and 94.12%, respectively) and specificity (91.53% and 81.58%, respectively). Multivariate analysis showed an increased risk of cancer in patients with levels of T<3 ng/mL, T to TPSA ratio <0.29 and E /TPSA <0.002642.
Discussion and Conclusions: The risk of prostate cancer is associated with low levels of T/PSAT ratio and E/TPSA ratio that increase the TPSA specificity. Showing ratios T/TPSA and E/TPSA had high sensitivity and specificity, so they could considered as prostate cancer risk predictors.